Inspired by our purpose to revolutionise care for people and planet, our sustainability roadmap to 2030, WeCare, guides us and lends structure to our sustainability efforts. It is a driver for growth, innovation and productivity and an essential part of our employee value proposition.

Our ambition is to transform our business to become a global leader in sustainable healthcare

Revolutionising care

Following a materiality analysis in 2021, we launched WeCare. Based on the Paris Agreement and the UN Sustainable Development Goals, WeCare embeds social, environmental, and economic value for patients and healthcare providers across our product and service offering. It also directs how we conduct our business in the short- mid- and long-term to create a sustainable, equitable and inclusive future.

  • Mölnlycke reviews a materiality analysis at least every second year to identify which issues to prioritise, manage and monitor to create shared value for society, the environment and the economy, as well as identify future challenges and opportunities for the company. In the 2022 materiality analysis, various stakeholders, including Mölnlycke’s employees, customers, distributors, suppliers, national sector organisations and students helped to identify 20 material aspects that were of primary importance, and prepared the ground for the company’s WeCare roadmap.

    The results showed that topics such as decent safe employment, diversity equity and inclusion, waste and circularity, sustainable innovation and development, and community support gained importance compared to the last materiality analysis in 2020. Other material aspects, such as biodiversity and responsible taxation approach, were found to have a lower significance.

    In 2023 Mölnlycke started to prepare for the Corporate Sustainability Reporting Directive (CSRD) and Corporate Sustainability Due Diligence Directive (CS3D) implementation by performing a Double Materiality assessment and consequent gap analysis

"Recognising the profound and ongoing pressure on environment, society and global healthcare systems in particular, Mölnlycke are accelerating our transformation to deliver sustainable healthcare solutions. We are uniquely positioned to improve patient lives while reducing the environmental impact of healthcare."

Zlatko Rihter Chief Executive Officer

Ethical business

We set high standards of ethics and responsibility in our business and act with integrity and care for human rights throughout our value chain.

Our commitment to reach Net Zero by 2050

We've formalised our climate change mitigation efforts by publicly committing to the Science Based Targets Initiative (SBTi), and securing their validation of our near-term climate targets, detailed below:

  • Reducing absolute scope 1 and 2 GHG emissions by 50% by 2030 from a 2021 base year.

  • Increasing active annual sourcing of renewable electricity from 23% in 2021 to 100% by the end of 2024 and continuing active annual sourcing of 100% of renewable electricity through 2030.

  • Reducing absolute scope 3 GHG emissions from purchased goods and services (cat. 1), fuel and energy related activity (cat. 3), upstream transportation and distribution (cat. 4) and waste generated in operations (cat. 5) by 20% by 2028 from a 2021 base year.

  • Having 63% of our suppliers by emissions covering purchased goods and services (cat. 1) capital goods (cat. 2), and upstream transportation and distribution (cat. 4) committed to the Science Based Targets Initiative by 2028.

Milestones on the way to Net Zero

2016: Scope 1 and 2 GHG emissions measured and baseline established.

2021: Materiality analysis and development of WeCare (2030 sustainability roadmap).

2021: Upstream and downstream scope 3 GHG emissions measured and baseline established.

2021: First range of BARRIER® surgical drapes launched with demonstrable reductions in emissions.

2022: Commitment to SBTi and nine manufacturing sites operating on 100% fossil-free electricity.

2023: Validation of near-term GHG emission reduction targets by SBTi.

2023: Sustainable Product Portfolio Assessment conduced for Operation Room Solutions and Antiseptics portfolios.